Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study

Jeffrey M Clarke,Jyoti D Patel,Francisco Robert,Ebenezer A Kio,Eddie Thara,D Ross Camidge,Martin Dunbar,Silpa Nuthalapati,Minh H Dinh,Bruce A Bach

Lung Cancer（2021）

引用 13|浏览33

暂无评分

摘要

•Veliparib, a PARP inhibitor, enhances cytotoxicity induced by chemotherapy (CT).•Nivolumab, a PD-1 inhibitor, plus CT demonstrated efficacy for NSCLC treatment.•This is a phase 1 trial of veliparib + nivolumab + CT in unresectable stage III NSCLC.•This quadruple therapy was tolerated, and no drug-drug interaction was observed.•This combination suggests promising antitumor activity.

查看译文

关键词

AUC0-x,AUCt,AUC∞,AE,AUC,BID,C,CI,Cmax,C/PAC,C/PEM,CT,CTCAE,CV,D,DDI,DLT,ECOG,h,HPLC LC-MS/MS,LLOQ,NCI,NSCLC,ORR,PARP,PARylation,PD-1,PD-L1,PD-L2,PK,PS,RECIST,RP2D,TEAE,Tmax,TNM

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要